Advertisement

Systemic Therapy of Central Nervous System Metastases of Breast Cancer

  • José Pablo LeoneEmail author
  • Nancy U. Lin
Breast Cancer (B Overmoyer, Section Editor)
  • 371 Downloads
Part of the following topical collections:
  1. Topical Collection on Breast Cancer

Abstract

Purpose of the Review

Historically, systemic treatment options for patients with breast cancer brain metastases have been very limited. This review focuses on important considerations for systemic therapy as well as ongoing clinical trials evaluating novel agents.

Recent Findings

For patients with hormone receptor-positive brain metastases, endocrine therapy or chemotherapy options can be considered. The role of CDK4/6 inhibitors is being explored in ongoing trials. Patients with HER2-positive disease have a number of treatment options, including ado-trastuzumab emtansine (TDM1) or lapatinib-capecitabine, and there is emerging evidence of the efficacy of neratinib- and tucatinib-based chemotherapy combinations in the CNS. Triple-negative tumors may respond to chemotherapy.

Summary

Although much progress remains to be made, a number of effective systemic treatment options are emerging, particularly for patients with HER2-positive disease. Ongoing clinical trials will help define the role of novel agents.

Keywords

Breast cancer Brain metastases Chemotherapy Targeted therapies Metastatic breast cancer 

Notes

Compliance with Ethical Standards

Conflict of Interest

José Pablo Leone has received research funds paid to his institution (University of Iowa) from Merck and has also received research funds from Kazia Therapeutics and Eli Lilly.

Nancy U. Lin has received funding for clinical trials from Genentech, Seattle Genetics, Novartis, and Pfizer, and has received compensation from Puma and Daiichi for service as a consultant.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(17):3608–17.  https://doi.org/10.1200/JCO.2004.01.175.CrossRefGoogle Scholar
  2. 2.
    Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(20):3271–7.  https://doi.org/10.1200/JCO.2009.25.9820.PubMedCrossRefGoogle Scholar
  3. 3.
    Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638–45.  https://doi.org/10.1002/cncr.23930.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013;14(3):244–8.  https://doi.org/10.1016/S1470-2045(13)70017-2.PubMedCrossRefGoogle Scholar
  5. 5.
    Sperduto PW, Kased N, Roberge D, Chao ST, Shanley R, Luo X, et al. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neuro-Oncol. 2013;112(3):467–72.  https://doi.org/10.1007/s11060-013-1083-9.PubMedCrossRefGoogle Scholar
  6. 6.
    Lee SS, Ahn JH, Kim MK, Sym SJ, Gong G, Ahn SD, et al. Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat. 2008;111(3):523–30.  https://doi.org/10.1007/s10549-007-9806-2.PubMedCrossRefGoogle Scholar
  7. 7.
    Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys. 2012;82(5):2111–7.  https://doi.org/10.1016/j.ijrobp.2011.02.027.CrossRefGoogle Scholar
  8. 8.
    Leone JP, Leone J, Zwenger AO, Iturbe J, Leone BA, Vallejo CT. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis. Eur J Cancer. 2017;74:17–25.  https://doi.org/10.1016/j.ejca.2016.12.015.PubMedCrossRefGoogle Scholar
  9. 9.
    Klos KJ, O'Neill BP. Brain metastases. Neurologist. 2004;10(1):31–46.  https://doi.org/10.1097/01.nrl.0000106922.83090.71.PubMedCrossRefGoogle Scholar
  10. 10.
    Gil-Gil MJ, Martinez-Garcia M, Sierra A, Conesa G, Del Barco S, Gonzalez-Jimenez S, et al. Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline. Clin Transl Oncol. 2014;16(5):436–46.  https://doi.org/10.1007/s12094-013-1110-5.PubMedCrossRefGoogle Scholar
  11. 11.
    Leone JP, Leone BA. Breast cancer brain metastases: the last frontier. Exp Hematol Oncol. 2015;4:33.  https://doi.org/10.1186/s40164-015-0028-8.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Lentzsch S, Reichardt P, Weber F, Budach V, Dorken B. Brain metastases in breast cancer: prognostic factors and management. Eur J Cancer. 1999;35(4):580–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Ogawa K, Yoshii Y, Nishimaki T, Tamaki N, Miyaguni T, Tsuchida Y, et al. Treatment and prognosis of brain metastases from breast cancer. J Neuro-Oncol. 2008;86(2):231–8.  https://doi.org/10.1007/s11060-007-9469-1.PubMedCrossRefGoogle Scholar
  14. 14.
    Hung MH, Liu CY, Shiau CY, Hsu CY, Tsai YF, Wang YL, et al. Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients. PLoS One. 2014;9(2):e89389.  https://doi.org/10.1371/journal.pone.0089389.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Leone JP, Lee AV, Brufsky AM. Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. Cancer Med. 2015;4(7):989–94.  https://doi.org/10.1002/cam4.439.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol. 2008;19(7):1242–8.  https://doi.org/10.1093/annonc/mdn036.PubMedCrossRefGoogle Scholar
  17. 17.
    Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17(14):4834–43.  https://doi.org/10.1158/1078-0432.CCR-10-2962.PubMedCrossRefGoogle Scholar
  18. 18.
    Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011;117(8):1602–11.  https://doi.org/10.1002/cncr.25746.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Melisko ME, Moore DH, Sneed PK, De Franco J, Rugo HS. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neuro-Oncol. 2008;88(3):359–65.  https://doi.org/10.1007/s11060-008-9578-5.CrossRefGoogle Scholar
  20. 20.
    Nieder C, Marienhagen K, Astner ST, Molls M. Prognostic scores in brain metastases from breast cancer. BMC Cancer. 2009;9:105.  https://doi.org/10.1186/1471-2407-9-105.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Shenker RF, Hughes RT, McTyre ER, Lanier C, Lo HW, Metheny-Barlow L, et al. Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone. J Radiosurg SBRT. 2018;5(4):277–83.Google Scholar
  22. 22.
    Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70(2):510–4.  https://doi.org/10.1016/j.ijrobp.2007.06.074.PubMedCrossRefGoogle Scholar
  23. 23.
    Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez-MacGregor M, Tripathy D, et al. Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(20):2239–45.  https://doi.org/10.1200/JCO.2014.58.8517.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(25):3069–103.  https://doi.org/10.1200/JCO.2016.67.1487.PubMedCrossRefGoogle Scholar
  25. 25.
    Colomer R, Cosos D, Del Campo JM, Boada M, Rubio D, Salvador L. Brain metastases from breast cancer may respond to endocrine therapy. Breast Cancer Res Treat. 1988;12(1):83–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Pors H, von Eyben FE, Sorensen OS, Larsen M. Long-term remission of multiple brain metastases with tamoxifen. J Neuro-Oncol. 1991;10(2):173–7.CrossRefGoogle Scholar
  27. 27.
    Stewart DJ, Dahrouge S. Response of brain metastases from breast cancer to megestrol acetate: a case report. J Neuro-Oncol. 1995;24(3):299–301.CrossRefGoogle Scholar
  28. 28.
    Madhup R, Kirti S, Bhatt ML, Srivastava PK, Srivastava M, Kumar S. Letrozole for brain and scalp metastases from breast cancer—a case report. Breast. 2006;15(3):440–2.  https://doi.org/10.1016/j.breast.2005.07.006.PubMedCrossRefGoogle Scholar
  29. 29.
    Goyal S, Puri T, Julka PK, Rath GK. Excellent response to letrozole in brain metastases from breast cancer. Acta Neurochir. 2008;150(6):613–4; discussion 614-615.  https://doi.org/10.1007/s00701-008-1576-z.PubMedCrossRefGoogle Scholar
  30. 30.
    Ito K, Ito T, Okada T, Watanabe T, Gomi K, Kanai T, et al. A case of brain metastases from breast cancer that responded to anastrozole monotherapy. Breast J. 2009;15(4):435–7.  https://doi.org/10.1111/j.1524-4741.2009.00756.x.PubMedCrossRefGoogle Scholar
  31. 31.
    Lien EA, Wester K, Lonning PE, Solheim E, Ueland PM. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer. 1991;63(4):641–5.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Raub TJ, Wishart GN, Kulanthaivel P, Staton BA, Ajamie RT, Sawada GA, et al. Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. Drug Metab Dispos. 2015;43(9):1360–71.  https://doi.org/10.1124/dmd.114.062745.PubMedCrossRefGoogle Scholar
  33. 33.
    Sahebjam S, Le Rhun E, Kulanthaivel P, Turner PK, Klise S, Wang HT, Tolaney SM (2016) Assessment of concentrations of abemaciclib and its major active metabolites in plasma, CSF, and brain tumor tissue in patients with brain metastases secondary to hormone receptor positive (HR+) breast cancer. Am Soc Clin OncolGoogle Scholar
  34. 34.
    Tolaney SM, Lin NU, Thornton D, Klise S, Costigan TM, Turner PK, et al. Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer. J Clin Oncol. 2017;35(15_suppl):1019–9.  https://doi.org/10.1200/JCO.2017.35.15_suppl.1019.CrossRefGoogle Scholar
  35. 35.
    Niwinska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol. 2010;21(5):942–8.  https://doi.org/10.1093/annonc/mdp407.PubMedCrossRefGoogle Scholar
  36. 36.
    Kaplan MA, Isikdogan A, Koca D, Kucukoner M, Gumusay O, Yildiz R, et al. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology). Oncology. 2012;83(3):141–50.  https://doi.org/10.1159/000338782.PubMedCrossRefGoogle Scholar
  37. 37.
    Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34.  https://doi.org/10.1056/NEJMoa1413513.PubMedCrossRefGoogle Scholar
  38. 38.
    Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(11):2349–51.CrossRefGoogle Scholar
  39. 39.
    Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87(5):586–92.  https://doi.org/10.1038/clpt.2010.12.CrossRefGoogle Scholar
  40. 40.
    Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med. 2013;54(11):1869–75.  https://doi.org/10.2967/jnumed.112.118612.PubMedCrossRefGoogle Scholar
  41. 41.
    Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neuro-Oncol. 2007;85(3):311–7.  https://doi.org/10.1007/s11060-007-9420-5.CrossRefGoogle Scholar
  42. 42.
    Yap YS, Cornelio GH, Devi BC, Khorprasert C, Kim SB, Kim TY, et al. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer. 2012;107(7):1075–82.  https://doi.org/10.1038/bjc.2012.346.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Park BB, Uhm JE, Cho EY, Choi YL, Ji SH, Nam DH, et al. Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes? Cancer Chemother Pharmacol. 2009;63(4):627–33.  https://doi.org/10.1007/s00280-008-0779-6.PubMedCrossRefGoogle Scholar
  44. 44.
    Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116–21.  https://doi.org/10.1093/annonc/mdu133.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.  https://doi.org/10.1056/NEJMoa1209124.PubMedCrossRefGoogle Scholar
  46. 46.
    Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26(1):113–9.  https://doi.org/10.1093/annonc/mdu486.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P, et al. Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clin Exp Metastasis. 2015;32(7):729–37.  https://doi.org/10.1007/s10585-015-9740-3.CrossRefGoogle Scholar
  48. 48.
    Jacot W, Pons E, Frenel JS, Guiu S, Levy C, Heudel PE, et al. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Res Treat. 2016;157(2):307–18.  https://doi.org/10.1007/s10549-016-3828-6.PubMedCrossRefGoogle Scholar
  49. 49.
    Fabi A, Alesini D, Valle E, Moscetti L, Caputo R, Caruso M, et al. T-DM1 and brain metastases: clinical outcome in HER2-positive metastatic breast cancer. Breast. 2018;41:137–43.  https://doi.org/10.1016/j.breast.2018.07.004.PubMedCrossRefGoogle Scholar
  50. 50.
    Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(12):1993–9.  https://doi.org/10.1200/JCO.2007.12.3588.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452–9.  https://doi.org/10.1158/1078-0432.CCR-08-1080.PubMedCrossRefGoogle Scholar
  52. 52.
    Sutherland S, Ashley S, Miles D, Chan S, Wardley A, Davidson N, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases—the UK experience. Br J Cancer. 2010;102(6):995–1002.  https://doi.org/10.1038/sj.bjc.6605586.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol. 2011;22(3):625–30.  https://doi.org/10.1093/annonc/mdq434.PubMedCrossRefGoogle Scholar
  54. 54.
    Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neuro-Oncol. 2011;105(3):613–20.  https://doi.org/10.1007/s11060-011-0629-y.PubMedCrossRefGoogle Scholar
  55. 55.
    Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71.  https://doi.org/10.1016/S1470-2045(12)70432-1.PubMedCrossRefGoogle Scholar
  56. 56.
    Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533–43.  https://doi.org/10.1007/s10549-007-9885-0.PubMedCrossRefGoogle Scholar
  57. 57.
    Pivot X, Manikhas A, Zurawski B, Chmielowska E, Karaszewska B, Allerton R, et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(14):1564–73.  https://doi.org/10.1200/JCO.2014.57.1794.CrossRefGoogle Scholar
  58. 58.
    Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(8):1301–7.  https://doi.org/10.1200/JCO.2009.25.8707.CrossRefGoogle Scholar
  59. 59.
    Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(32):3626–33.  https://doi.org/10.1200/JCO.2014.56.3809.CrossRefGoogle Scholar
  60. 60.
    Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol. 2016;2(12):1557–64.  https://doi.org/10.1001/jamaoncol.2016.0237.PubMedCrossRefGoogle Scholar
  61. 61.
    Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, et al. Translational Breast Cancer Research Consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(9):945–52.  https://doi.org/10.1200/JCO.2015.63.0343.CrossRefGoogle Scholar
  62. 62.
    • Freedman RA, Gelman RS, Melisko ME, Anders CK, Moy B, Blackwell KL, Connolly RM, Niravath PA, Van Poznak CH, Puhalla S (2017) TBCRC 022: Phase II trial of neratinib+ capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM). Am Soc Clin Oncol. This study describes the benefit of the combination of neratinib with capecitabine in patients with HER2-positive brain metastases. Google Scholar
  63. 63.
    Metzger O, Barry W, Krop I, Guo H, Younger J, Lawler E, Walker L, Freedman R, Tolaney S, Winer E (2017) Abstract P1-12-04: phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastases. AACRGoogle Scholar
  64. 64.
    • Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(7):880–8.  https://doi.org/10.1016/S1470-2045(18)30256-0 This manuscript reports the first results of tucatinib in combination with capecitabine and trastuzumab for the treatment of HER2-positive brain metastases. PubMedCrossRefGoogle Scholar
  65. 65.
    Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer. 1986;58(4):832–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer. 1992;69(4):972–80.PubMedCrossRefGoogle Scholar
  67. 67.
    Linot B, Campone M, Augereau P, Delva R, Abadie-Lacourtoisie S, Nebout-Mesgouez N, et al. Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study. J Neuro-Oncol. 2014;117(2):253–9.  https://doi.org/10.1007/s11060-014-1378-5.CrossRefGoogle Scholar
  68. 68.
    Caraglia M, Addeo R, Costanzo R, Montella L, Faiola V, Marra M, et al. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol. 2006;57(1):34–9.  https://doi.org/10.1007/s00280-005-0001-z.PubMedCrossRefGoogle Scholar
  69. 69.
    Cocconi G, Lottici R, Bisagni G, Bacchi M, Tonato M, Passalacqua R, et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Investig. 1990;8(3–4):327–34.CrossRefGoogle Scholar
  70. 70.
    Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fosser V, Tonato M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer. 1999;85(7):1599–605.PubMedCrossRefGoogle Scholar
  71. 71.
    Lorusso V, Galetta D, Giotta F, Rinaldi A, Romito S, Brunetti C, et al. Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell’Italia Meridionale). Anticancer Res. 2006;26(3B):2259–63.PubMedGoogle Scholar
  72. 72.
    Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S, et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada–Clinical Trials Group (NCIC-CTG). Ann Oncol. 2006;17(6):952–6.  https://doi.org/10.1093/annonc/mdl056.PubMedCrossRefGoogle Scholar
  73. 73.
    Christodoulou C, Bafaloukos D, Linardou H, Aravantinos G, Bamias A, Carina M, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) phase II study. J Neuro-Oncol. 2005;71(1):61–5.  https://doi.org/10.1007/s11060-004-9176-0.CrossRefGoogle Scholar
  74. 74.
    Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006;107(6):1348–54.  https://doi.org/10.1002/cncr.22127.PubMedCrossRefGoogle Scholar
  75. 75.
    Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neuro-Oncol. 2007;85(2):223–7.  https://doi.org/10.1007/s11060-007-9409-0.CrossRefGoogle Scholar
  76. 76.
    Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, et al. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat. 2014;146(3):557–66.  https://doi.org/10.1007/s10549-014-3039-y.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    • Cortes J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, et al. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat. 2017;165(2):329–41.  https://doi.org/10.1007/s10549-017-4304-7 This study describes the benefit seen among patients with brain metastases with the use of etirinotecan pegol. PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    • Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–63.  https://doi.org/10.1056/NEJMoa1802905 This study reports the role of the PARP inhibitor talazoparib in metastatic breast cancer. PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medical Oncology, Division of Breast Oncology, Dana-Farber Cancer InstituteHarvard Medical SchoolBostonUSA

Personalised recommendations